Equity (Details) $ / shares in Units, shares in Millions, dose in Millions, $ in Millions		1 Months Ended			9 Months Ended
	Mar. 18, 2021 USD ($)	Feb. 28, 2022 USD ($) $ / shares shares	Apr. 30, 2021 USD ($) $ / shares shares	Feb. 28, 2021 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) dose $ / shares	Dec. 31, 2021 USD ($) $ / shares	Mar. 01, 2021 dose $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares						$ 0.01	$ 0.01
Purchase obligation		$ 14.3
Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding					$ 5.0	$ 4.1	$ 5.0
Series B Warrants | Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input					0.15
COVAXIN Preferred Stock Purchase Agreement | Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Agreement to sell, number of shares issued in transaction (in shares) | shares								0.1
Convertible preferred stock, par value (in USD per share) | $ / shares								$ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares								$ 109.60
Advance payment amount	$ 6.0
Conversion ratio (in shares)								10
Supply agreement, number of doses | dose						10.0		10.0
Public Offering Of Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares		16.0
Price per share (in USD per share) | $ / shares		$ 3.13
Proceeds from sale of stock		$ 49.8
Registered Direct Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares			10.0	3.0
Price per share (in USD per share) | $ / shares			$ 10.00	$ 7.65
Proceeds from sale of stock			$ 93.4	$ 21.2
Commissions, fees and expenses			$ 6.6	$ 1.7
ATMs
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares					1.0
Proceeds from sale of stock					$ 4.8
Commissions, fees and expenses					$ 0.1